Company expects to file an IND for the drug later this year.
ProNAi Therapeutics signed a supply agreement with Polymun Scientific to manufacture the company’s PNT2258 DNAi®-based cancer therapeutic.
Polymun will use its cross-flow injector technology to produce ProNAi’s liposome-formulated candidate, which is in the final stages of preclinical toxicology testing. ProNAi reports that it intends to bring PNT2258 to IND submission later this year.
“ProNAi is confident that Polymun’s manufacturing processes and technology are state-of-the-art and up to the task of formulating our oncology drug candidate, which features our novel oligo delivery method for the safe and effective administration of nucleic acid-based therapies,” states Richard D. Gill, president and CEO of ProNAi.
